Research Update: Boston Scientific Corp. Outlook Revised To Negative On Continued Pressures For Key Franchises;'A-'Ratings Affirmed - S&P Global Ratings’ Credit Research

Research Update: Boston Scientific Corp. Outlook Revised To Negative On Continued Pressures For Key Franchises;'A-'Ratings Affirmed

Research Update: Boston Scientific Corp. Outlook Revised To Negative On Continued Pressures For Key Franchises;'A-'Ratings Affirmed - S&P Global Ratings’ Credit Research
Research Update: Boston Scientific Corp. Outlook Revised To Negative On Continued Pressures For Key Franchises;'A-'Ratings Affirmed
Published Nov 06, 2026
Published Nov 06, 2026
Price US$ 225.00  |  Buy this Report Now

About This Report

  
Abstract:

Boston Scientific Corp. has continued to underperform as key growth drivers, including its WATCHMAN and electrophysiology (EP) franchises, face market and competitive headwinds. S&P Global Ratings anticipates the company will sustain this underperformance into 2027 as it seeks to stabilize market share and restore growth. We project revenue growth of 4.4% for 2026 and 9% for 2027, well below the mid- to high-teens percentages achieved in 2024-2025. The prolonged slowdown in revenue growth means S&P Global Ratings-adjusted leverage will likely remain elevated above our downside trigger of 2.5x for an extended period following the planned $14.5 billion acquisition of Penumbra Inc., expected to close in early 2027. Therefore, we affirmed our ‘A-’ issuer credit rating on Boston Scientific and ‘A-’

  
Report Type:

Research Update

Ticker
BSX
Issuer
Sumitomo Mitsui Banking Corp. (Dusseldorf Branch)
GICS
Health Care Equipment (35101010)
Sector
Global Issuers
Country
United States
Region
United States
Format:
PDF Adobe Acrobat
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Research Update: Boston Scientific Corp. Outlook Revised To Negative On Continued Pressures For Key Franchises;'A-'Ratings Affirmed" Nov 06, 2026. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/s-and-p-credit-research/Research-Update-Boston-Scientific-Corp-Outlook-Revised-To-Negative-On-Continued-Pressures-For-Key-Franchises-A-Ratings-Affirmed-3656346>
  
APA:
S&P Global Ratings’ Credit Research. (). Research Update: Boston Scientific Corp. Outlook Revised To Negative On Continued Pressures For Key Franchises;'A-'Ratings Affirmed Nov 06, 2026. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/s-and-p-credit-research/Research-Update-Boston-Scientific-Corp-Outlook-Revised-To-Negative-On-Continued-Pressures-For-Key-Franchises-A-Ratings-Affirmed-3656346>
  
US$ 225.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.